Funding Opportunity RFA-HL-18-013 from the NIH Guide for Grants and Contracts. The objective of this research career program is to create a national Consortium that focuses on career development of the next generation of biomedical investigators in glycosciences. The ultimate goal of the Consortium is to transform and democratize glycosciences from a super-specialized research domain into the mainstream of biology and clinical translation such that glycans become an integral component of future scholars'/investigators' scientific thinking, thus creating a pathway for major scientific breakthroughs specifically in heart, lung, blood and sleep (HLBS) sciences.

Notice NOT-MH-17-017 from the NIH Guide for Grants and Contracts

Notice NOT-AI-17-022 from the NIH Guide for Grants and Contracts

Notice NOT-AI-17-021 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-052 from the NIH Guide for Grants and Contracts

Notice NOT-AA-17-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-245 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.

Funding Opportunity PA-17-246 from the NIH Guide for Grants and Contracts. This FOA issued by AHRQ invites grant applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes.

Funding Opportunity PA-17-248 from the NIH Guide for Grants and Contracts. The overarching goal of this Funding Opportunity Announcement (FOA) is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise.

Notice NOT-HL-17-499 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-498 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-500 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-502 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-505 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-504 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-503 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-497 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-496 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-506 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-004 from the NIH Guide for Grants and Contracts. Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.